交银医药创新股票A（004075）成立日期2017年3月23日，最新规模19亿。今年以来收益0.08%，同类排 名5014/5572；近一年收益19.93%，同类排名3002/4311；成立以来收益160.4%。 2月26日，毕得医药跌1.67%，截至发稿，报57.78元/股，成交4981.73万元，换手率1.99%，总市值52.51 亿元。毕得医药股价已经连续5天下跌，区间累计跌幅5.76%。 资料显示，上海毕得医药科技股份有限公司位于上海市杨浦区翔殷路999号3幢6层，成立日期2007年4月 27日，上市日期2022年10月11日，公司主营业务涉及聚焦于新药研发产业链前端,依托药物分子砌块的 研发设计、生产及销售等核心业务,能够为新药研发机构提供结构新颖、功能多样的药物分子砌块及科 学试剂等产品。主营业务收入构成为：分子砌块杂环化合物43.26%，分子砌块苯环化合物23.32%，分 子砌块脂肪族类化合物16.36%，催化剂和配体10.57%，生命科学试剂6.49%。 从毕得医药十大流通股东角度 数据显示，交银施罗德基金旗下1只基金位居毕得医药十大流通股东。交银医药创新股票A（004075） 三季度新进十大 ...

Group 1 - The core business of Shanghai Bid Pharma focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [2] - As of September 30, 2025, Bid Pharma achieved operating revenue of 979 million yuan, a year-on-year increase of 20.67%, and a net profit attributable to shareholders of 120 million yuan, up 42.79% year-on-year [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Group 2 - As of January 26, 2025, Bid Pharma's financing balance is 33.27 million yuan, accounting for 1.09% of its market capitalization, which is below the 30th percentile level over the past year [1] - On January 26, 2025, Bid Pharma had a net financing buy of -347,900 yuan, with a financing buy of 477,400 yuan and a financing repayment of 512,190 yuan [1] - The company has a total of 3,493 shareholders as of September 30, 2025, a decrease of 7.64% from the previous period, while the average circulating shares per person increased by 8.27% to 12,377 shares [2][3]

Core Viewpoint - The stock of Yaoshi Technology has shown fluctuations in price and trading volume, with a notable increase in revenue but a decrease in net profit for the year 2025 [1][2]. Group 1: Stock Performance - On January 21, Yaoshi Technology's stock rose by 2.08%, reaching 43.67 CNY per share, with a trading volume of 1.84 billion CNY and a turnover rate of 2.11%, resulting in a total market capitalization of 10.21 billion CNY [1]. - Year-to-date, the stock price has increased by 13.25%, but it has decreased by 8.51% over the last five trading days [1]. - The stock has shown a 13.31% increase over the last 20 days and a 7.09% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Yaoshi Technology reported a revenue of 1.419 billion CNY, reflecting a year-on-year growth of 25.81% [2]. - The net profit attributable to shareholders for the same period was 113 million CNY, which represents a year-on-year decrease of 13.96% [2]. Group 3: Shareholder Information - As of December 31, the number of shareholders for Yaoshi Technology was 42,500, a decrease of 1.09% from the previous period [2]. - The average number of tradable shares per shareholder increased by 1.10% to 4,770 shares [2]. - The company has distributed a total of 231 million CNY in dividends since its A-share listing, with 137 million CNY distributed over the last three years [3].

Group 1 - Bid Medicine's stock price fell by 5.04% on January 20, closing at 66.00 yuan per share, with a trading volume of 52.74 million yuan and a turnover rate of 1.81%, resulting in a total market capitalization of 5.998 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.12% during this period [1] - Bid Medicine focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] Group 2 - Among the top ten circulating shareholders of Bid Medicine, a fund under E Fund, specifically E Fund Value Growth Mixed Fund (110010), entered the top ten with 900,000 shares, accounting for 2.08% of circulating shares [2] - The estimated floating loss for E Fund Value Growth Mixed Fund today is approximately 3.15 million yuan, with a total floating loss of 4.077 million yuan during the three-day decline [2] - E Fund Value Growth Mixed Fund has a total asset size of 3.288 billion yuan, with a year-to-date return of 3.74% and a one-year return of 38.06% [2]

Group 1 - Bid Pharma's stock increased by 5.07% to 68.44 CNY per share, with a trading volume of 68.3753 million CNY and a turnover rate of 2.38%, resulting in a total market capitalization of 6.22 billion CNY [1] - The company, established on April 27, 2007, focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Morgan Stanley Fund has a significant holding in Bid Pharma, with the "Morgan Stanley Youyue Anhe Mixed A" fund reducing its holdings by 15,300 shares to 53,000 shares, representing 6.6% of the fund's net value, making it the third-largest holding [2] - The fund has a total scale of 29.6292 million CNY and has achieved a year-to-date return of 8.64%, ranking 427 out of 8,827 in its category, and a one-year return of 26.74%, ranking 4,492 out of 8,084 [2]

Group 1 - The core business of Shanghai Bid Pharmaceutical Technology Co., Ltd. focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [2] - As of September 30, 2025, the company achieved operating revenue of 979 million yuan, a year-on-year increase of 20.67%, and a net profit attributable to shareholders of 120 million yuan, up 42.79% year-on-year [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Group 2 - On December 31, Bid Pharmaceutical's stock rose by 0.66%, with a trading volume of 59.01 million yuan [1] - The financing buy-in amount on December 31 was 2.45 million yuan, while the financing repayment was 4.40 million yuan, resulting in a net financing buy-in of -1.95 million yuan [1] - The total balance of margin trading as of December 31 was 33.48 million yuan, accounting for 1.27% of the circulating market value, which is below the 30th percentile level over the past year [1]

Group 1 - The core viewpoint of the news is that Yaoshi Technology's stock has seen a slight increase, with a current price of 39.20 yuan per share and a total market capitalization of 9.165 billion yuan [1] - Yaoshi Technology, established on December 26, 2006, and listed on November 10, 2017, is based in Nanjing, Jiangsu Province, and specializes in the research, development, production, and sales of drug molecular building blocks [1] - The company's main business revenue composition includes 83.14% from drug development and commercialization services, 16.72% from drug research services, and 0.14% from other sources [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Yaoshi Technology, having increased its holdings by 230,300 shares in the third quarter, totaling 1.7054 million shares, which represents 0.84% of the circulating shares [2] - The Southern CSI 1000 ETF has achieved a year-to-date return of 29.2%, ranking 1850 out of 4195 in its category, and a one-year return of 24.73%, ranking 2053 out of 4179 [2] - The fund manager of Southern CSI 1000 ETF, Cui Lei, has a total asset scale of 122.76 billion yuan, with the best fund return during the tenure being 207.47% and the worst being -15.93% [3]

Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a year-to-date increase of 54.24%, indicating strong market performance and investor interest [1][2]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the period from January to September 2025, Bid Pharma achieved operating revenue of 979 million yuan, representing a year-on-year growth of 20.67%. The net profit attributable to the parent company was 120 million yuan, reflecting a year-on-year increase of 42.79% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Bid Pharma was 3,493, a decrease of 7.64% from the previous period. The average number of circulating shares per person increased by 8.27% to 12,377 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and others, with several new entrants and some exiting the list [3].

Core Insights - Bid Pharma's stock increased by 5.01% to 75.90 CNY per share, with a total market capitalization of 6.898 billion CNY as of the report date [1] Company Overview - Shanghai Bid Pharma Technology Co., Ltd. was established on April 27, 2007, and went public on October 11, 2022 [1] - The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - Main business revenue composition includes: - 43.26% from molecular building block heterocyclic compounds - 23.32% from molecular building block aromatic compounds - 16.36% from molecular building block aliphatic compounds - 10.57% from catalysts and ligands - 6.49% from life science reagents [1] Fund Holdings - One fund under Bank of China Securities holds a significant position in Bid Pharma, specifically the Bank of China Securities Health Industry Mixed Fund (002938) [2] - In Q3, this fund reduced its holdings by 40,000 shares, maintaining a total of 118,000 shares, which represents 5.7% of the fund's net value [2] - The fund has achieved a year-to-date return of 35.86% and a one-year return of 30.27% [2]

Group 1 - The core viewpoint of the news is that Bid Pharma has seen a stock price increase of 5.01%, reaching 75.90 CNY per share, with a total market capitalization of 6.898 billion CNY [1] - Bid Pharma focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - The Guotou Ruijin Healthcare Mixed A Fund holds 53,200 shares of Bid Pharma, accounting for 2.84% of the fund's net value, ranking as the ninth largest holding [2] - The fund has achieved a year-to-date return of 32.49%, ranking 2279 out of 8136 in its category [2] - The fund manager, Liu Zexu, has a tenure of 2 years and 71 days, with the best fund return during this period being 31.19% [3]